newsfilter
← Latest News
Business Wire·

Xencor Announces Change to Ultomiris® Royalty Revenue Forecast

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced that Alexion Pharmaceuticals, Inc. (the